Shionogi has announced positive efficacy results from a Phase IIa proof-of-concept trial of S-2367, a drug candidate for obesity and related conditions.
The unique mechanism of action of S-2367 involves blocking receptor binding of neuropeptide Y (NPY), a neurotransmitter involved in regulation of energy balance and food consumption. NPY levels are particularly elevated in reduced-weight or food-deprived subjects, resulting in stimulation of food intake. S-2367 was designed to counteract elevated NPY levels, promoting continued weight loss.
Shionogi assessed the safety and efficacy of S-2367 once-daily treatment in a population of 342 obese subjects across 20 sites in the U.S. The study met its primary endpoint and demonstrated a statistically significant effect in maintaining and continuing weight loss in the subjects.